Helsinki Ultra-acute Stroke Biomarker Study
Helsinki Ultra-acute Stroke Biomarker Study
The aim of this study is to establish diagnostic and predictive biomarkers for patients with
 suspected acute stroke, that are transported by EMS as candidates for thrombolytic treatment.
 The study focuses on the ultra acute phase, <4.5 hours from symptom onset, including the
 prehospital setting. Analyses will include known biomarkers (e.g. GFAP, NR2 peptide) and a
 discovery phase for novel markers. Patient outcome will be evaluated at 3 month using the
 modified Rankin Scale (mRS).
Inclusion Criteria:

 -  Acute stroke suspected by EMS personnel

 -  Transport to tertiary hospital as possible candidate for thrombolytic treatment of
 ischemic stroke

 -  Age ≥18

 -  Successful prehospital blood sampling by EMS personnel

 Exclusion Criteria:

 -  Unsuccessful prehospital blood sampling by EMS personnel